Vaccines and Biologics for Global Health Crises
The project, led by HIPRA and co-funded by the European Union and HaDEA, aims to transform the development and manufacturing process of vaccines and biologics, making it faster, more reliable, and more scalable in the context of health emergencies.
The project is aligned with European strategies to strengthen health security and address the systemic shortage of medicines, particularly in the context of health crises and pandemics. To respond to this need, SPEEDCELL focuses on optimizing cell line–based development and manufacturing processes with the goal of achieving the “100 Days Goal”—drastically reducing the time required to develop and distribute vaccines and biologics to 100 days or less in emergency situations.
For more information, visit the SPEEDCELL Project website.
Cofunded by the European Union under grant agreement No 101136439. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union (EU) or European Health and Digital Executive Agency (HaDEA). Neither the EU nor HaDEA can be held responsible for them.
